Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 8 of 24
<< Start
< Prev
3
4
5
6
7
8
9
10
11
12
Next >
End >>
08.04.2020
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform
Press Release
07.04.2020
Amphista Therapeutics raises $7.5m Series A round to advance targeted protein degradation assets in cancer
Press Release
18.02.2020
New company takes aim at treatments for multiple sclerosis
Press Release
13.01.2020
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
Press Release
22.12.2019
Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration with MSD Phase II Trial
Press Release
14.11.2019
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications
Press Release
11.11.2019
F2G Receives US FDA Breakthrough Therapy Designation for Olorofim
Press Release
09.09.2019
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Press Release
26.04.2019
Acutus Medical’s New Contact Mapping Software Receives CE Mark
Press Release
18.04.2019
Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA
Press Release
©2022 Advent Life Sciences